GHK-Cu — glycyl-L-histidyl-L-lysine copper(II) — is one of the most widely studied peptides in regenerative and cosmetic science, and one of the few research peptides that Peptide Data grades Moderate rather than Limited. That grade is not a therapeutic claim: it reflects an extensive in vitro and animal literature plus a smaller, growing body of human cosmetic-dermatology data. This explainer sets out where the evidence is genuinely strong, where it thins out, and why GHK-Cu's UK status differs from that of most research peptides.
1. What GHK-Cu is
GHK-Cu is a naturally occurring copper-binding tripeptide — three amino acids, glycine–histidine–lysine — first isolated from human plasma in 1973 [R1]. It is not a synthetic drug scaffold; the sequence occurs in human plasma, and the copper(II) ion is integral to its behaviour rather than an incidental additive. It is studied in wound-healing, tissue-repair and skin-remodelling research, and it also appears in cosmetic formulations [R2][R3].
2. Mechanism: copper delivery plus gene-expression modulation
GHK-Cu's activity is best understood in two parts.
First, it delivers copper. The copper(II) ion is a cofactor for enzymes including lysyl oxidase (which cross-links collagen and elastin), superoxide dismutase (antioxidant defence) and tyrosinase (pigmentation). By chelating copper, GHK-Cu improves its bioavailability and cellular uptake relative to free copper ions [R4][R5].
Second, it modulates gene expression. Work by Pickart and colleagues reported that GHK-Cu alters the expression of a large set of genes — on the order of several thousand — upregulating genes associated with tissue repair and downregulating inflammatory and degenerative ones [R2]. The peptide also stimulates fibroblast proliferation, collagen synthesis (types I and III) and angiogenesis in laboratory models [R2][R3].
That combination — a defined metal-binding chemistry alongside broad transcriptional effects — is why GHK-Cu attracts interest beyond dermatology. It is also why the mechanism is easier to describe than to reduce to a single molecular target.
3. Evidence base: extensive in vitro and animal data, thinner human data
The preclinical record is large. In vitro studies repeatedly demonstrate fibroblast stimulation and collagen synthesis, and animal models support wound-healing and tissue-repair effects [R2][R3][R4].
The human record is smaller and different in character. It is concentrated in cosmetic dermatology, where GHK-Cu has been studied as a topical ingredient; a 2015 review in Advances in Wound Care summarised its role in skin repair and regeneration [R2]. Two limitations are worth stating plainly. The human literature is limited in size, and a substantial part of it is industry-funded. There are no large-scale randomised controlled trials of systemic GHK-Cu in humans [R2][R3].
4. Why GHK-Cu grades Moderate
Peptide Data's four-tier scale — Strong, Moderate, Limited, Anecdotal — is anchored to human data. Most research peptides sit at Limited because their evidence stops at animal models. GHK-Cu reaches Moderate because human data exists: it has been studied in people, in a defined and largely topical cosmetic context, on top of a deep mechanistic literature [R2][R3].
Moderate is not a synonym for "proven". It means the human evidence is real but limited — smaller than the evidence base for licensed medicines, and shaped by the commercial interests of the cosmetics sector. Readers should treat it as a statement about the strength of the literature, not as a claim that GHK-Cu treats, cures or prevents any condition.
5. UK legal status
GHK-Cu is not a licensed medicine in the UK and is not controlled under the Misuse of Drugs Act 1971. Peptide Data's live profile records its UK status as Legal. It is sold as a research chemical for laboratory use.
Topical GHK-Cu also appears in cosmetic products, which are regulated in the UK under cosmetics legislation rather than medicines law. The MHRA does not regulate GHK-Cu as a medicinal product unless specific medicinal claims are made for it — at which point it would be assessed as an unlicensed medicine, and supplying an unlicensed medicine for human use breaches the Human Medicines Regulations 2012 [R6], with the underlying licensing regime set out in the Medicines Act 1968. Laboratory handling of the compound also falls under UK chemicals and workplace safety legislation, which is separate from medicines law.
The distinction matters: a cosmetic ingredient is not a licensed medicine, and the two are governed by different regimes.
6. Reading GHK-Cu claims
Because GHK-Cu sits at Moderate and appears in consumer cosmetics, it attracts stronger marketing language than most research peptides. Three checks are useful when reading such claims. First, ask whether the cited study was in vitro, animal or human — the answer changes the weight of the claim. Second, ask whether the human study was independent or industry-funded. Third, note that cosmetic use is topical, whereas much of the striking mechanistic data comes from cell-culture and animal work; the two should not be conflated.
7. Research-use-only
GHK-Cu is not a licensed medicine in the UK and is not approved for human consumption. This article describes published research findings and UK regulatory status; it is not medical advice, and it does not recommend or describe how GHK-Cu should be used in humans. Peptide Data does not provide consumption, dosing or self-administration guidance for any compound.
This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.